Metastatic renal carcinoma (mRCC) is very hard to cure, despite the use of new-generation therapies that include inhibitors of key proteins such as tyrosine kinases (TK) and blockers that stimulate the immune response against cancer cells called immune checkpoint inhibitors (ICIs). The gene discussed is TKT; the disease is cancer.